Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075400 · OUTCOME

Overall Survival

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From study entry to death or last contact, up to 5 years.

What was measured

The observed length of life from entry into the study to death or the date of last contact

Analysis population: Eligible and treated patients

Groups in this outcome

Gleevec

Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gleevec23

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Gleevec4.1Not reported3.38.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.3
        upper Limit
        8.6
        value
        4.1
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
The observed length of life from entry into the study to death or the date of last contact
dispersion Type
95% Confidence Interval
groups
  1. description
    Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.
    id
    OG000
    title
    Gleevec
param Type
MEDIAN
population Description
Eligible and treated patients
reporting Status
POSTED
time Frame
From study entry to death or last contact, up to 5 years.
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice